top of page

NCI-2020-03931

Updated: Feb 21

A Phase 1 Study of SGN-B6A in Advanced Solid Tumors


This Phase 1 study investigates the safety and tolerability of SGN-B6A in patients with advanced solid tumors. It aims to determine the maximum tolerated dose of the drug while assessing its pharmacokinetics and preliminary effectiveness against various types of advanced solid cancers. The study sets the foundation for further research into SGN-B6A as a potential treatment option for these challenging conditions.


For more information about the trial, click the link below:

Clinical Trial Site: Columbia


To see all available clinical trials click here.



 
 
 

Recent Posts

See All
NCI-2025-06021

Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer (TRIPL) This is a research study exploring how combining radiation therapy with dual immune check

 
 
 
NCI-2024-05588

A Randomized Phase III Trial INcorporating Pathologic Complete ReSponse in Participants with Early StaGe Non Small Cell Lung Cancer to Optimize ImmunotHerapy in the AdjuvanT Setting (INSIGHT) The INSI

 
 
 
NCI-2022-08569

Randomized Phase III Trial of mFOLFIRINOX /- Nivolumab vs. FOLFOX /- Nivolumab for First-Line Treatment of Metastatic HER2-Negative Gastroesophageal Adenocarcinoma This randomized Phase III research

 
 
 

Comments

bottom of page